Effect of Exposure to Pill Contraceptive Low-dose Levels  of Homocysteine and Nitric Oxide in Healthy Women

Dehghani, A; Momeni, z; Fallahzadeh, H; Dafei, M; Hekmati moghaddam, H; Mojibian, M; Nogh, H

Volume 24, Issue 4 (Jul 2016) JSSU 2016, 24(4): 352-362 | Back to browse issues page

Mendeley

Zotero

RefWorks

Dehghani A, Momeni Z, Fallahzadeh H, Dafei M, Hekmati moghaddam H, Mojibian M et al . Effect of Exposure to Pill Contraceptive Low-dose Levels of Homocysteine and Nitric Oxide in Healthy Women. JSSU 2016; 24 (4) :352-362
URL: http://jssu.ssu.ac.ir/article-1-3514-en.html

Effect of Exposure to Pill Contraceptive Low-dose Levels of Homocysteine and Nitric Oxide in Healthy Women

A Dehghani

, Z Momeni ^*

, H Fallahzadeh

, M Dafei

, H Hekmati moghaddam

, M Mojibian

, H Nogh

Abstract: (8449 Views)

Introduction: Cardiovascular disease is one of the public health priorities. Consumption of oral contraceptives increase the risk of cardiovascular disease and it still remains a concern. This study aimed to investigate the effect of exposure on pill contraceptive low-dose levels on homocysteine and nitric oxide.

methods: In this cohort ( retrospective+ prospective) study, 100 women with normal menstrual cycle aged betwen 20-35 years old refered to health care centers of Yazd, Iran in 2015. This study was conducted through face to face interviews by the researcher who asked for demographic and anthropometric characteristics. Anthropometic indices was measured and the levels of homosysteine and nitric oxide was determined. The data were analyzed using t-test, chi- square test and ANOVA by SPSS 21.

Results: The mean and standard deviation of homocysteine levels in the exposed group acompared to non-exposed group were (3/848±2/357 μmol/L) and (3/284±1/616 μmol/L) as well as the mean and standard deviation of nitric oxide in the exposed group were (p-value=0/41) and (181/360±90/44μM) and in the non-exposed group were (162/654±90/913 μM) and (p-value=0/29) , respectively.According to these results, there was not found any statistical significant difference among these results.

Conclusion: Taking low dose oral contraceptives in healthy women did not change any differences in homocysteine and nitric oxide levels as a modifiable risk factors for cardiovascular disease.

Keywords: Oral Contraceptive Pills, Homocystein, Nitric Oxide, Cohort Study

Full-Text [PDF 449 kb] (1943 Downloads)

Type of Study: Original article | Subject: General
Received: 2015/12/9 | Accepted: 2016/05/2 | Published: 2016/09/27

References

1. Qureshi Z, Taleghani F, Shafie M. Evaluation of failure and complications of oral contraceptives to Caravans Hajj pilgrims delayed menarche in Kerman Province in 1379-80. J Shaeed Sdoughi University of Medical Sciences Yazd 2004; 12(4): 65-70. [Persian]

2. Noah jah S, Soori H. Relationship between combined oral contraceptives use of twinning in the next pregnancy. Feyz 2005; 9(2): 53-6. [Persian]

3. Baillargeon J-P, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrino Metabolism 2005; 90(7): 3863-70.

4. Vaisy A, Lotfinejad S, Zhian F. Relationship between utrine cervical carcinoma and oral contraceptives. J Gorgan Uni Med Sci 2012; 14(3): 98-103. [Persian]

5. Rosendaal F, Helmerhorst F, Vandenbroucke J. Female hormones and thrombosis. Arteriosclerosis, thrombosis, and vascular biology 2002; 22(2): 201-10.

6. Akbarzadehpasha H. Principles of drug use in women. 2, editor: Pasha; 2013. [Persian]

7. Zakharova MY, Meyer RM, Brandy KR, Datta YH, Joseph MS, Schreiner PJ, et al. Risk factors for heart attack, stroke, and venous thrombosis associated with hormonal contraceptive use. Clinical Applied Thrombosis/Hemostasis 2011; 17(4): 323-31.

8. Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci 2003; 73(10): 1245-52.

9. Akbarzadeh M, SHarifi N. Comparison of cardiovascular disease in women with OCP use and without OCP use in hospitals of Shiraz university of medical sciences. Iran J Nurs Res (IJNR) 2013; 8(28): 19-28. [Persian]

10. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. Jama 2003; 289(10): 1251-7.

11. Azizi F, Saadat N, Rahmani M, Emami H, Mirmiran P, Hajipoor R. Cardiovascular risk factors in Tehran urban population: Tehran Lipid and Glucose Study (Final Report Phase I). J Res Med Sci 2002; 26(1): 43-55.

12. Farag N, Barshop B, Mills P. Effects of estrogen and psychological stress on plasma homocysteine levels. Fertil Steril 2003; 79(1): 256-60.

13. Bukowska H, Stanosz S, Żochowska E, Millo B, Sieja K, Chełstowski K, et al. Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women? Metabolism 2005; 54(1): 72-8.

14. Ardawi SM, Rouzi AA, Qari MH, Dahlawi FM, Al-Raddadi RM. Influence of age, sex, folate and vitamin B12 status on plasma homocysteine in Saudis. Saudi Med J 2002; 23(8): 959-68.

15. Fallah S, Nouroozi V, Seifi M, Samadikuchaksaraei A, Aghdashi EM. Influence of oral contraceptive pills on homocysteine and nitric oxide levels: As risk factors for cardiovascular disease. J Clin Lab Analysis 2012; 26(2): 120-3.

16. Merki-Feld GS, Imthurn B, Keller PJ. Effects of two oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism. Metabolism 2002; 51(9): 1216-21.

17. Lussana F, Zighetti ML, Bucciarelli P, Cugno M, Cattaneo M. Blood levels of homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives compared to non-users. Thrombosis Res 2003; 112(1): 37-41.

18. Mirzaei N, Dehpour A. Investigation of Homocystein Plasma Level in Cholestatic Rat and Its Effect on Nitric Oxide Secretion in Liver. Sceintific J Hamadan University Med Sci 2005; 12(1): 25-34. [Persian]

19. Mirershadi F, Faghihi M, Dehpour AR. Effect of endogenous nitric oxide on cardiac ischemic preconditioning in rat. Bimonthly J Hormozgan University of Medical Sciences 2010; 14(1): 13-21. [Persian]

20. Taheripanah R, Hosseini M, Kazemi M, Zamani E. The amount of homocysteine in patients with recurrent miscarriage and normal fertile women. Iran J Obstetrics Gynecology Infertility 2010; 13(2): 1-6. [Persian]

21. Farahmand M, Ramazani tehrani F, Norouzzadeh M, Azizi F. relationship between risk factors of cardiovascular disease in women of reproductive age with oral contraceptive pills consumption. Medical Science J Islamic Azad Univesity Tehran Medical Branch 2015; 24(4): 242-7. [Persian]

22. Akhavan tabib A, Saeedi M, Bahonar A, KHosravi A, Dana siadat Z, Alikhasi H. Its serum concentration of triglycerides and waist size in women with cardiovascular risk factors of central Iran (Isfahan Healthy Heart Program). Jundishapur Scientific Medical J 2009; 7(2): 223-33. [Persian]

23. Tohidi M, Assadi M, Dehghani Z, Vahdat K, Emami S, Nabopour I. High sensitive C-reactive protein and ischemic heart disease, a population- based study. Iran South Med 2012; 15(4): 253-62. [Persian]

24. Esmaillzadeh A, Mirmiran P, Azizi F. Waist-to-hip ratio is a better screening measure for cardiovascular risk factors than other anthropometric indicators in Tehranian adult men. Int J Obesity 2004; 28(10): 1325-32.

25. Gaini A, Lamei T. The relationship between the percentage of fat (% BF), body mass index (BMI) and waist to hip ratio (WHR) women fifteen years in Tehran. Harakat 2003; 17(17): 95-105. [Persian]

26. Rafraf M, Mahdavi R, Rashidi M, Koshavar H, Farzdi L. Serum vitamin A status of women consuming oral contraceptive pills. Yafteh 2005; 7(1): 61-70. [Persian]

27. Eini E, Mirmiran P, Allah verdian S, Azizi F. Contraceptives and cardiovascular risk factors in women in Tehran (Tehran Lipid and Glucose Study). Journal of Research In Medical Sciences. 2000;26 (2): 123-8.

28. Wang C, Li Y, Bai J, Qian W, Zhou J, Sun Z, et al. General and central obesity, combined oral contraceptive use and hypertension in Chinese women. Am J Hypertens 2011; 24(12): 1324-30.

29. Lech MM, L O. Effects of low-dose OCs on weight in women with central European nutritional habits and lifestyle. Contraception 2002; 66(3): 159-62.

30. Morris MS, Jacques PF, Selhub J, Rosenberg IH. Total Homocysteine and Estrogen Status Indicators in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2000; 152(2): 140-8.

31. Tallova J, Tomandl J, Bicikova M, Hill M. Changes of plasma total homocysteine levels during the menstrual cycle. European J Clin Investiga 1999;29(12): 1041-4.

32. Green TJ, Houghton LA, Donovan U, Gibson RS, O'Connor DL. Oral contraceptives did not affect biochemical folate indexes and homocysteine concentrations in adolescent females. J Academy Nutrit Dietetics 1998; 98(1): 49.

33. Steegers-Theunissen R, Boers G, Steegers E, Trijbels F, Thomas C, TK E. Effects of sub-50 oral contraceptives on homocysteine metabolism: a preliminary study. Contraception. 1992; 45(2): 129-39.

34. Beaumont V, Malinow M, Sexton G, Wilson D, Lemort N, Upson B, et al. Hyperhomocysteinemia, anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives. Atherosclerosis 1992; 94(2-3): 147-52.

35. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Bmj 2002; 325(7374): 1202.

36. Boger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst (e) inemia or hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2000; 20(6): 1557-64.

37. Herrmann M, Taban‐Shomal O, Hübner U, Böhm M, Herrmann W. A review of homocysteine and heart failure. Euro J Heart Failure 2006; 8(6): 571-6.